|
|
|||||||||
|
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: [email protected]. Type 508 Accommodation and the title of the report in the subject line of e-mail. Update: Ralstonia Species Contamination Associated with Vapotherm® 2000i Respiratory Gas Humidifier Systems --- United States, 2005--2006This report updates previously published information regarding contamination of Vapotherm® 2000i respiratory gas humidifiers (Vapotherm, Inc., Stevensville, Maryland) with Ralstonia species (1--3). The manufacturer took corrective actions (Table) and reintroduced the device in January 2007, after meeting Food and Drug Administration (FDA) 510(k) submission requirements.* CDC and FDA recommend that clinicians using the Vapotherm device ensure that they are following the most recent recommendations and have the most recent instructions for the device and its components; the 2000i operating instruction manual can be obtained by contacting Vapotherm, Inc., by telephone: 410-604-3977 or 866-827-6843, fax: 410-604-3978, or e-mail: [email protected]. Additional information regarding use of the reintroduced device is available from FDA at http://www.fda.gov/cdrh/safety/020107-vapotherm.html. FDA encourages reporting of adverse events related to the use of medical devices; such reports can be submitted to MedWatch, FDA's voluntary reporting program, by telephone: 1-800-FDA-1088, by fax: 1-800-FDA-0178, by mail: MedWatch, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20852-9787, or online: http://www.fda.gov/medwatch/report.htm. Clinicians who would like to conduct surveillance for health-care--associated infections in patients using the Vapotherm device can use strategies similar to those used for surveillance of ventilator-associated infections. Reported by: A Srinivasan, MD, National Center for Preparedness, Detection, and Control of Infectious Diseases (proposed); M Jhung, MD, EIS Officer, CDC. References
* Additional information is available at http://www.fda.gov/cdrh/devadvice/314.html.
Disclaimer All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices. **Questions or messages regarding errors in formatting should be addressed to [email protected].Date last reviewed: 3/1/2007 |
|||||||||
|